AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32125052 — intervention group
Group type: COMPARATOR
Intervention: Standard interface
Number of subjects: 50
Study 36163721 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Number of subjects: 111
Study 36163721 — intervention group
Group type: COMPARATOR
Intervention: ChT
Number of subjects: 111
Study 34273987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous LPS (Escherichia coli O113, 2 ng/kg)
Number of subjects: 10
Study 34273987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 36469573 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant durvalumab (monotherapy)
Number of subjects: 20
Study 36469573 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus tremelimumab (combination therapy)
Number of subjects: 20
Study 34118298 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib 0.25% ointment
Number of subjects: 0
Study 34118298 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment (control)
Number of subjects: 0
Study 34118298 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib 0.25% or 0.5% ointment (Part 2)
Number of subjects: 0
Study 32947424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone adjunct to risperidone
Number of subjects: 64
Study 32947424 — intervention group
Group type: COMPARATOR
Intervention: Placebo adjunct to risperidone
Number of subjects: 64
Study 35477444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound visual biofeedback (U‐VBF)
Number of subjects: 40
Study 35477444 — intervention group
Group type: COMPARATOR
Intervention: Standard articulatory intervention
Number of subjects: 40
Study 33004234 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP Air (n = 30)
Number of subjects: 61
Study 33004234 — intervention group
Group type: COMPARATOR
Intervention: Information-and-referral control intervention (n = 31)
Number of subjects: 61
Study 36349299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on the triglyceride-glucose index
Number of subjects: 1073
Study 35714121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component rehabilitation intervention including access to an information book about cardiac disease, patient supporters, information materials for employers, rehabilitation goal setting plan, support café for relatives, follow-up phone calls from physiotherapists, and additional support for vulnerable patients.
Number of subjects: 182
Study 35714121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component rehabilitation intervention as described above.
Number of subjects: 182
Study 35714121 — intervention group
Group type: COMPARATOR
Intervention: Usual care at the hospital including rehabilitation-needs-assessment, patient education, and physical training.
Number of subjects: 182
Study 32316014 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD-guided BP control (TBC)
Number of subjects: 95
Study 32316014 — intervention group
Group type: COMPARATOR
Intervention: Non-TCD-guided BP control (NBC)
Number of subjects: 95
Study 35346889 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal glycemic control (fasting and 1-hour postprandial or serial intrapartum capillary blood glucose screening with insulin treatment as indicated)
Number of subjects: 86
Study 35346889 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (no glucose screening or treatment)
Number of subjects: 86
Study 33635171 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS) for 12 weeks followed by monthly maintenance treatment
Number of subjects: 116
Study 33965514 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCP model based on mandible bone D30% and pre-RT dental extraction
Number of subjects: 1259
Study 34083504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (HDM)
Number of subjects: 321
Study 34083504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 321
Study 34083504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 321
Study 34083504 — intervention group
Group type: COMPARATOR
Intervention: MRD-negative patients
Number of subjects: 321
Study 33730349 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glucose disposal rate (eGDR)
Number of subjects: 32
Study 33730349 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk group (56% of patients)
Number of subjects: 32
Study 32384922 — intervention group
Group type: EXPERIMENTAL
Intervention: Logbook
Number of subjects: 235
Study 32384922 — intervention group
Group type: COMPARATOR
Intervention: No logbook
Number of subjects: 235
Study 33741732 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (375 mg, once per day)
Number of subjects: 28
Study 33741732 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (500 mg, once per day)
Number of subjects: 28
Study 33741732 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (250 mg, once per day)
Number of subjects: 28
Study 33359589 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of PTAH (cohorts 1 and 3A)
Number of subjects: 358
Study 33359589 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-daily dosing of PTAH (cohorts 2, 3B, and 3C)
Number of subjects: 358
Study 33359589 — intervention group
Group type: COMPARATOR
Intervention: PTAH-naive participants receiving 300 mg/d PTAH
Number of subjects: 358
Study 33359589 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAH-continuing participants
Number of subjects: 358
Study 33359589 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAH treatment beyond 1 year
Number of subjects: 358
Study 33359589 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in immune markers with PTAH continuation
Number of subjects: 358
Study 32194196 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 4731
Study 32194196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 35364479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task intervention (DTI)
Number of subjects: 38
Study 35364479 — intervention group
Group type: EXPERIMENTAL
Intervention: Iranian dance intervention (IDI)
Number of subjects: 38
Study 35596975 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based chatbot conversations
Number of subjects: 20
Study 37072702 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted laryngoscopy with Macintosh-shaped blade
Number of subjects: 2500
Study 37072702 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted laryngoscopy with hyperangulated blade
Number of subjects: 2500
Study 37072702 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy with Macintosh blade (standard of care)
Number of subjects: 2500
Study 33495008 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 4 IU/day subcutaneous injection
Number of subjects: 156
Study 33495008 — intervention group
Group type: COMPARATOR
Intervention: Control group (subcutaneous saline)
Number of subjects: 156
Study 35093490 — intervention group
Group type: EXPERIMENTAL
Intervention: DI+TAU
Number of subjects: 83
Study 35093490 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 83
Study 34602396 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with dexmedetomidine and propofol combined with seaweed polysaccharides
Number of subjects: 82
Study 34602396 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia with sufentanil combined with propofol
Number of subjects: 82
Study 34882571 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Decision Support Tool (DST)
Number of subjects: 196
Study 34882571 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Decision Support Tool (DST)
Number of subjects: 196
Study 34882571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DST)
Number of subjects: 196
Study 32746948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar food/beverage advertisements
Number of subjects: 101
Study 32746948 — intervention group
Group type: COMPARATOR
Intervention: Toy advertisements
Number of subjects: 101
Study 32251844 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (synergism group)
Number of subjects: 171
Study 32251844 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (additivism/indifference group)
Number of subjects: 171
Study 32251844 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (antagonism group)
Number of subjects: 171
Study 32251844 — intervention group
Group type: COMPARATOR
Intervention: Colistin monotherapy (control group)
Number of subjects: 171
Study 32341244 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadlifts performed with lifting straps (DLw)
Number of subjects: 16
Study 32341244 — intervention group
Group type: COMPARATOR
Intervention: Deadlifts performed without lifting straps (DLn)
Number of subjects: 16
Study 34958402 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication therapy for osteoporosis
Number of subjects: 3670
Study 34958402 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with periodontal disease
Number of subjects: 3670
Study 34958402 — intervention group
Group type: COMPARATOR
Intervention: Subjects without periodontal disease
Number of subjects: 3670
Study 34259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 300
Study 34259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit attempts
Number of subjects: 300
Study 34259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit
Number of subjects: 300
Study 34259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness to quit smoking
Number of subjects: 300
Study 34259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of smoking cessation medication
Number of subjects: 300
Study 33855995 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy intervention (electronic digital storyboards)
Number of subjects: 150
Study 33855995 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 32967393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashi acupuncture
Number of subjects: 35
Study 32967393 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injections
Number of subjects: 35
Study 32991509 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite training (COMP group, n = 10)
Number of subjects: 21
Study 32991509 — intervention group
Group type: COMPARATOR
Intervention: Sprint training (SPRINT group, n = 11)
Number of subjects: 21
Study 34790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 90
Study 34790041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 90
Study 34790041 — intervention group
Group type: COMPARATOR
Intervention: Blank group (no HBOT)
Number of subjects: 90
Study 32819988 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted mass media campaign (TV, radio, print media and social media)
Number of subjects: 676
Study 33146706 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum TPT initiation
Number of subjects: 0
Study 33146706 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum TPT initiation
Number of subjects: 0
Study 33146706 — intervention group
Group type: COMPARATOR
Intervention: Antepartum TPT initiation with nevirapine
Number of subjects: 0
Study 33146706 — intervention group
Group type: COMPARATOR
Intervention: Postpartum TPT initiation with nevirapine
Number of subjects: 0
Study 35974933 — intervention group
Group type: EXPERIMENTAL
Intervention: ISR with MACE
Number of subjects: 30
Study 35974933 — intervention group
Group type: COMPARATOR
Intervention: ISR without MACE
Number of subjects: 30
Study 34340163 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy (PT) treatment including exercise instructions from the first postoperative day
Number of subjects: 157
Study 34340163 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 157
Study 34340163 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy (PT) treatment
Number of subjects: 157
Study 35976959 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week interval (males)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week interval (males)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: COMPARATOR
Intervention: 12-week interval (males)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week interval (females)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week interval (females)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: COMPARATOR
Intervention: 16-week interval (females)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: COMPARATOR
Intervention: 8-week vs 12-week interval (males)
Number of subjects: 44863
Study 35976959 — intervention group
Group type: COMPARATOR
Intervention: 12-week vs 16-week interval (females)
Number of subjects: 44863
Study 33904585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Number of subjects: 47
Study 33904585 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 47
Study 33904585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 47
Study 32228235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 0
Study 32228235 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine augmentation
Number of subjects: 0
Study 36125177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated pre-discharge
Number of subjects: 991
Study 36125177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated post-discharge
Number of subjects: 991
Study 33411115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with epoetin beta pegol targeting hemoglobin level of 11 g/dL or higher
Number of subjects: 362
Study 33411115 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment maintaining hemoglobin levels at enrollment (within ± 1 g/dL)
Number of subjects: 362
Study 33411115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 362
Study 32407710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin supplementation (200 mg/kg once daily)
Number of subjects: 1542
Study 32407710 — intervention group
Group type: COMPARATOR
Intervention: No lactoferrin supplement (control group)
Number of subjects: 1542
Study 32407710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin supplementation (meta-analysis)
Number of subjects: 1542
Study 32407710 — intervention group
Group type: COMPARATOR
Intervention: Control group (meta-analysis)
Number of subjects: 1542
Study 34358324 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-SXB 9 g
Number of subjects: 222
Study 34358324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 33783237 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 20
Study 33783237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35175011 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching (Whiteness HP Maxx) for three sessions of 45 min
Number of subjects: 75
Study 35175011 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with PNF desensitizing gel (Desensibilize KF 2%) applied for 10 min before each session
Number of subjects: 75
Study 35175011 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with N desensitizing paste (Desensibilize Nano P) applied after bleaching for 5 min
Number of subjects: 75
Study 34088270 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia (fentanyl boluses of 1.0 µg/kg to maintain SPI value between 20 and 50)
Number of subjects: 62
Study 34088270 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia techniques (fentanyl boluses of 1.0 µg/kg administered when HR or MAP increased to 20% above baseline or HR > 90 bpm)
Number of subjects: 62
Study 34088270 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia
Number of subjects: 62
Study 34088270 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia techniques
Number of subjects: 62
Study 36501157 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive diabetes education intervention
Number of subjects: 0
Study 36501157 — intervention group
Group type: COMPARATOR
Intervention: Standard education on COVID-19
Number of subjects: 0
Study 33626417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled samples from batches of slaughter pigs processed twice by two individual samplers.
Number of subjects: 30
Study 33626417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling of single pigs in 30 randomly selected pig pens within the farms.
Number of subjects: 30
Study 33626417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregating the resistance abundance at gene family or antimicrobial class level.
Number of subjects: 30
Study 32320024 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose fiber (7 g/d)
Number of subjects: 50
Study 32320024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fiber (3 g/d)
Number of subjects: 50
Study 32320024 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 35399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethiodized poppyseed oil-based contrast medium
Number of subjects: 1026
Study 35399811 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast medium
Number of subjects: 1026
Study 32779606 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐PGA/TCP
Number of subjects: 5
Study 32779606 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐PGA
Number of subjects: 5
Study 32779606 — intervention group
Group type: COMPARATOR
Intervention: α‐TCP
Number of subjects: 5
Study 32779606 — intervention group
Group type: COMPARATOR
Intervention: CPP‐ACP
Number of subjects: 5
Study 32779606 — intervention group
Group type: COMPARATOR
Intervention: deionized water
Number of subjects: 5
Study 34524022 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart (FiAsp)
Number of subjects: 16
Study 34524022 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 16
Study 32105625 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing with task shifting to enrolled nurses
Number of subjects: 390
Study 32105625 — intervention group
Group type: COMPARATOR
Intervention: Laboratory viral load testing (standard-of-care group)
Number of subjects: 390
Study 36010630 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA‐LUT therapy
Number of subjects: 69
Study 34532268 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin + BSM (tamsulosin 0.2 mg, finasteride 5 mg, curcumin 2,250 mg once a day)
Number of subjects: 122
Study 34532268 — intervention group
Group type: COMPARATOR
Intervention: BSM (tamsulosin 0.2 mg, finasteride 5 mg, placebo)
Number of subjects: 122
Study 34532268 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin + BSM
Number of subjects: 122
Study 36315189 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated insulin dosing (AID)
Number of subjects: 120
Study 33433644 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg ASP8062
Number of subjects: 20
Study 33433644 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg ASP8062
Number of subjects: 20
Study 33433644 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 40 mg
Number of subjects: 20
Study 33433644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33126854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport to acute care centre
Number of subjects: 98
Study 33126854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport to geriatric ward
Number of subjects: 98
Study 33126854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport to emergency department
Number of subjects: 98
Study 35367385 — intervention group
Group type: COMPARATOR
Intervention: ONLINE‐ONLY (digital CBT‐I program)
Number of subjects: 240
Study 35367385 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPED‐CARE (triaged approach with Decision Checklist)
Number of subjects: 240
Study 34199155 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian method
Number of subjects: 69
Study 34199155 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurac method
Number of subjects: 69
Study 34199155 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques with stabilization techniques
Number of subjects: 69
Study 34965816 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a hypothetical RCT regardless of screening test result
Number of subjects: 100
Study 34965816 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization to either an intervention or control group
Number of subjects: 100
Study 34965816 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons to participate in the RCT
Number of subjects: 100
Study 34699549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 83
Study 34699549 — intervention group
Group type: COMPARATOR
Intervention: Heparin ± GPIs
Number of subjects: 83
Study 34839672 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrient-enriched supplement for 7 days
Number of subjects: 43
Study 34839672 — intervention group
Group type: COMPARATOR
Intervention: Standard high-protein normocaloric supplement (control) for 7 days
Number of subjects: 43
Study 32663638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home admission eligibility granted
Number of subjects: 0
Study 32663638 — intervention group
Group type: COMPARATOR
Intervention: Nursing home admission eligibility not granted
Number of subjects: 0
Study 36114953 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR neurofeedback
Number of subjects: 37
Study 35496724 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic treatment including spinal manipulation
Number of subjects: 132
Study 35496724 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic treatment including spinal manipulation, together with podiatric custom-made orthoses
Number of subjects: 132